In re Zetia (Ezetimibe) Antitrust Litig., No. 18-md-02836 (E.D. Va.)

In the Zetia case, Faruqi & Faruqi represents a class of direct purchasers of Merck & Co.’s Zetia (ezetimibe), a drug used to treat high cholesterol.  The case alleges that Merck entered into an unlawful reverse payment settlement with generic manufacturers Glenmark Pharmaceuticals and Par Pharmaceutical in 2010 to delay generic entry until late 2016. In exchange for this delay, Merck promised Glenmark and Par not to launch an authorized generic in competition with their generic Zetia for the first 180 days their product was on the market.  The direct purchasers paid supracompetitive prices as a result of delayed generic entry and the absence of competition from an authorized generic.

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.


Filed on 02/07/2018


1617 JFK Boulevard, Suite 1550

19103 Philadelphia, Pennsylvania

Phone (215) 277-5770

Fax (215) 277-5771


Joseph T. Lukens Phone (215) 277-5770 Fax (215) 277-5771

Peter Kohn Phone (215) 277-5770 Fax (215) 277-5771

Finding us

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331


1901 Avenue of the Stars Suite 1060
Los Angeles, California 90067
(424) 256-2884
(424) 256-2885


3565 Piedmont Road NE Building Four, Suite 380
Atlanta, Georgia 30305
(404) 847-0617
(404) 506-9534


1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania